Clinical trials are a very important part of the research process. New treatments, medications and medical devices cannot be approved for use in Australia without going through clinical trials. Find out more about clinical trials.
Antipsychotic dose reduction to improve recovery and function in young people with psychosis
The REDUCE study is testing whether reducing the dosage of antipsychotic medication of people recovering from their first episode of psychosis can lead to them having better recovery outcomes.
Cannabidiol (CBD) as a potential new treatment for mental ill-health in youths
The Cannabidiol for At Risk Youth (CanARY) study is testing a potential new treatment called cannabidiol (CBD) for helping people with symptoms that might indicate risk of a psychotic disorder. CBD is a non-psychoactive treatment, meaning it does not give you a ‘high’.
Neural mechanisms of ketamine antidepressant treatment
The NeuroKet study aims to understand how ketamine works as an antidepressant medication. To find out, we are looking at brain activity using Magnetic Resonance Imaging (MRI) scans.
New treatment for young people with depression
SKY-D is investigating whether ketamine is an effective treatment for young people with depression.
Psychedelic-assisted therapy for depression
This large international trial will examine the efficacy and safety of a new psychedelic-assisted therapy for treatment-resistant depression.
Survey for carers of individuals with mental illness
A survey to better understand the experiences of caregivers and siblings of people who have experienced a manic episode or psychosis.